EDARBI

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Estonia, Germany, Hong Kong SAR China, Ireland, Lithuania, Poland, UK.

Active ingredients

The drug EDARBI contains one active pharmaceutical ingredient (API):

1	Azilsartan medoxomil UNII LL0G25K7I2 - AZILSARTAN MEDOXOMIL
	Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
	Read more about Azilsartan medoxomil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EDARBI Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09CA09	Azilsartan medoxomil	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501114090023201
CA	Health Products and Food Branch	02381389, 02381397
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	03100009, 03100021, 09252973, 09252996, 09253004, 09253027, 09253033, 09253056, 09253079, 09253085, 09253116, 13963964, 14293052, 14293069, 17394799
EE	Ravimiamet	1550483, 1550494, 1550506, 1550517, 1550528, 1550539, 1550540, 1550551, 1550573, 1550584, 1550595, 1590285, 1590296, 1590308, 1590319, 1590320, 1590331, 1590342
GB	Medicines & Healthcare Products Regulatory Agency	203510, 203515, 203519
HK	Department of Health Drug Office	61807, 61808
IE	Health Products Regulatory Authority	51002, 51003, 51004
LT	Valstybinė vaistų kontrolės tarnyba	1064204, 1064205, 1064206, 1064207, 1064208, 1064209, 1064210, 1064211, 1064212, 1064213, 1064214, 1067657, 1067658, 1067659, 1067660, 1067661, 1067662, 1067663, 1089479, 1089480, 1089481, 1089482, 1089483, 1089484, 1089485, 1089486, 1089487, 1089489, 1089490, 1089491
PL	Rejestru Produktów Leczniczych	100309540, 100309556, 100309562
US	FDA, National Drug Code	60631-040, 60631-080